NEW YORK (GenomeWeb News) - Transgenomic said yesterday that it has struck agreements with two undisclosed pharmaceutical companies to provide genetic mutation discovery services for two Phase II clinical trials.

The company said the deals will be worth a total of $500,000 in the first half of 2008, but it did not disclose the names of the companies involved or provide further financial details.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.